Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.

Jack CR Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, Borowski B, Britson PJ, L Whitwell J, Ward C, Dale AM, Felmlee JP, Gunter JL, Hill DL, Killiany R, Schuff N, Fox-Bosetti S, Lin C, Studholme C, DeCarli CS, Krueger G, Ward HA, Metzger GJ, Scott KT, Mallozzi R, Blezek D, Levy J, Debbins JP, Fleisher AS, Albert M, Green R, Bartzokis G, Glover G, Mugler J, Weiner MW.

J Magn Reson Imaging. 2008 Apr;27(4):685-91. doi: 10.1002/jmri.21049.

2.

Volumetric MRI and cognitive measures in Alzheimer disease : comparison of markers of progression.

Ridha BH, Anderson VM, Barnes J, Boyes RG, Price SL, Rossor MN, Whitwell JL, Jenkins L, Black RS, Grundman M, Fox NC.

J Neurol. 2008 Apr;255(4):567-74. doi: 10.1007/s00415-008-0750-9. Epub 2008 Feb 18.

PMID:
18274807
3.

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.

Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC.

Brain. 2008 Mar;131(Pt 3):665-80. doi: 10.1093/brain/awm336. Epub 2008 Feb 7.

4.

Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment.

Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR Jr, Aisen PS, Thal LJ.

Neurology. 2008 Jan 15;70(3):191-9. doi: 10.1212/01.wnl.0000287091.57376.65.

PMID:
18195264
5.

Neuroimaging and APOE genotype: a systematic qualitative review.

Cherbuin N, Leach LS, Christensen H, Anstey KJ.

Dement Geriatr Cogn Disord. 2007;24(5):348-62. Epub 2007 Oct 2. Review.

PMID:
17911980
6.

Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease.

Devanand DP, Pradhaban G, Liu X, Khandji A, De Santi S, Segal S, Rusinek H, Pelton GH, Honig LS, Mayeux R, Stern Y, Tabert MH, de Leon MJ.

Neurology. 2007 Mar 13;68(11):828-36.

PMID:
17353470
7.

Relationship between the efficacy of rivastigmine and apolipoprotein E (epsilon4) in patients with mild to moderately severe Alzheimer disease.

Blesa R, Aguilar M, Casanova JP, Boada M, Martínez S, Alom J, de la Hoz CH, Sancho J, Fernández O, Gil-Neciga E, Massó JF.

Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):248-54.

PMID:
17132969
8.

Identification of responders and reactive domains to rivastigmine in Alzheimer's disease.

Frankfort SV, Appels BA, de Boer A, Tulner LR, van Campen JP, Koks CH, Beijnen JH, Schmand BA.

Pharmacoepidemiol Drug Saf. 2007 May;16(5):545-51.

PMID:
17109476
9.

Temporal horn index and volume of medial temporal lobe atrophy using a new semiautomated method for rapid and precise assessment.

Giesel FL, Hahn HK, Thomann PA, Widjaja E, Wignall E, von Tengg-Kobligk H, Pantel J, Griffiths PD, Peitgen HO, Schroder J, Essig M.

AJNR Am J Neuroradiol. 2006 Aug;27(7):1454-8.

10.

Volumetric correlates of memory and executive function in normal elderly, mild cognitive impairment and Alzheimer's disease.

Duarte A, Hayasaka S, Du A, Schuff N, Jahng GH, Kramer J, Miller B, Weiner M.

Neurosci Lett. 2006 Oct 2;406(1-2):60-5. Epub 2006 Aug 14.

11.

Shape differences of the brain ventricles in Alzheimer's disease.

Ferrarini L, Palm WM, Olofsen H, van Buchem MA, Reiber JH, Admiraal-Behloul F.

Neuroimage. 2006 Sep;32(3):1060-9. Epub 2006 Jul 12.

PMID:
16839779
12.

Ventricular volume and dementia progression in the Cardiovascular Health Study.

Carmichael OT, Kuller LH, Lopez OL, Thompson PM, Dutton RA, Lu A, Lee SE, Lee JY, Aizenstein HJ, Meltzer CC, Liu Y, Toga AW, Becker JT.

Neurobiol Aging. 2007 Mar;28(3):389-97. Epub 2006 Feb 28.

13.

Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI.

Jack CR Jr, Shiung MM, Weigand SD, O'Brien PC, Gunter JL, Boeve BF, Knopman DS, Smith GE, Ivnik RJ, Tangalos EG, Petersen RC.

Neurology. 2005 Oct 25;65(8):1227-31.

14.

Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.

Bizzarro A, Marra C, Acciarri A, Valenza A, Tiziano FD, Brahe C, Masullo C.

Dement Geriatr Cogn Disord. 2005;20(4):254-61. Epub 2005 Aug 9.

PMID:
16103669
15.

Measuring atrophy in Alzheimer disease: a serial MRI study over 6 and 12 months.

Schott JM, Price SL, Frost C, Whitwell JL, Rossor MN, Fox NC.

Neurology. 2005 Jul 12;65(1):119-24.

PMID:
16009896
16.

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M; AN1792(QS-21)-201 Study.

Neurology. 2005 May 10;64(9):1563-72.

PMID:
15883317
17.

Vitamin E and donepezil for the treatment of mild cognitive impairment.

Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ; Alzheimer's Disease Cooperative Study Group.

N Engl J Med. 2005 Jun 9;352(23):2379-88. Epub 2005 Apr 13.

18.

Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.

Visser PJ, Scheltens P, Pelgrim E, Verhey FR; Dutch ENA-NL-01 Study Group.

Dement Geriatr Cogn Disord. 2005;19(2-3):126-33. Epub 2004 Dec 23.

PMID:
15627759
19.

Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers.

Farlow M, Lane R, Kudaravalli S, He Y.

Pharmacogenomics J. 2004;4(5):332-5.

PMID:
15289797
20.

Mapping hippocampal and ventricular change in Alzheimer disease.

Thompson PM, Hayashi KM, De Zubicaray GI, Janke AL, Rose SE, Semple J, Hong MS, Herman DH, Gravano D, Doddrell DM, Toga AW.

Neuroimage. 2004 Aug;22(4):1754-66. Erratum in: Neuroimage. 2007 Jul 15;36(4):1397-8.

PMID:
15275931

Supplemental Content

Support Center